ZYMVOL develops computational methods for enzyme discovery and design using highly realistic simulations that mimic experimental conditions with over 90% accuracy. Its platform reduces development time and cost by allowing only the most promising variants to proceed to lab testing, and it can discover enzymes for a target reaction without prior data. Founded in 2017, the company has completed more than 100 projects, primarily for pharmaceutical and chemical clients including Axplora, Medichem, and Sanofi. Over the years it has partnered with R&D teams from some of the world’s largest firms to transform production processes and reduce environmental impact through tailored enzymatic solutions. CEO Maria Fátima Lucas says ZYMVOL aims to make enzymes accessible to everyone so green chemistry becomes the new norm. The company positions its technology as a way to boost innovation and strengthen industrial resilience across sectors. Zymvol designs and develops enzymes using highly realistic computer simulations of enzyme environments rather than relying solely on laboratory work. Its computational approach accelerates development by up to 50%, lowers costs, and yields a success rate above 75%. The company sells B2B services including prospect studies and full discovery, optimization, and laboratory validation for chemical, pharmaceutical and biotech clients. Zymvol aims to make enzymes accessible to companies seeking more efficient products and more sustainable processes, including reducing toxic waste through enzyme customization. The 28-person team is led by Dr. Maria Fatima Lucas, who has over 20 years of experience in protein science and computational chemistry; the company was founded in 2017. Recent financing is intended to grow the team, develop its new laboratory, scale production and validate the performance of its biomelanin. Zymvol uses computer simulations to discover and develop industrial enzymes. Its core product is a platform that models challenging factory-floor environments to engineer enzymes that tolerate pressure and temperature variations. The company says its simulations can achieve results in roughly half the time and at lower cost than traditional lab engineering. Zymvol also claims the approach can identify enzymes for a target reaction without prior knowledge, enabling serendipitous discoveries. Target markets include pharma, chemical and food industries and consumer products such as detergents, where enzymes can replace less sustainable catalysts and improve product properties. To accelerate discovery and development of new industrial enzymes, Zymvol raised €1.3 million in seed funding from Elaia Partners.

Total raised

$6M

Funding rounds

3

Latest round

Seed

Latest activity

Feb 2025